It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The pathogenesis of major depressive disorder (MDD) involves lipid metabolism. Our earlier research also revealed that MDD patients had much lower total cholesterol (TC) concentrations than healthy controls (HCs). However, it is still unclear why TC decreased in MDD. Here, based on the Ingenuity Knowledge Base’s ingenuity pathway analysis, we found that sodium voltage-gated channel alpha subunit 11A (SCN11A) might serve as a link between low lipid levels and MDD. We analyzed the TC levels and used ELISA kits to measure the levels of SCN11A in the serum from 139 MDD patients, and 65 HCs to confirm this theory and explore the potential involvement of SCN11A in MDD. The findings revealed that TC levels were considerably lower and SCN11A levels were remarkably increased in MDD patients than those in HCs, while they were significantly reversed in drug-treatment MDD patients than in drug-naïve MDD patients. There was no significant difference in SCN11A levels among MDD patients who used single or multiple antidepressants, and selective serotonin reuptake inhibitors or other antidepressants. Pearson correlation analysis showed that the levels of TC and SCN11A were linked with the Hamilton Depression Rating Scales score. A substantial association was also found between TC and SCN11A. Moreover, a discriminative model made up of SCN11A was discovered, which produced an area under a curve of 0.9571 in the training set and 0.9357 in the testing set. Taken together, our findings indicated that SCN11A may serve as a link between low lipid levels and MDD, and showed promise as a candidate biomarker for MDD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 The First Affiliated Hospital of Chongqing Medical University, Department of Neurology, Chongqing, China (GRID:grid.452206.7) (ISNI:0000 0004 1758 417X); The First Affiliated Hospital of Chongqing Medical University, National Health Commission Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, Chongqing, China (GRID:grid.452206.7) (ISNI:0000 0004 1758 417X)
2 The Second Affiliated Hospital of Chongqing Medical University, Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, Chongqing, China (GRID:grid.412461.4); Chongqing Medical University, Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing, China (GRID:grid.203458.8) (ISNI:0000 0000 8653 0555)
3 Chongqing Medical University, Institute of Life Sciences, Chongqing, China (GRID:grid.203458.8) (ISNI:0000 0000 8653 0555)
4 The First Affiliated Hospital of Chongqing Medical University, Department of Neurology, Chongqing, China (GRID:grid.452206.7) (ISNI:0000 0004 1758 417X)
5 Third Military Medical University (Army Medical University), Department of Clinical Laboratory, Xinqiao Hospital, Chongqing, China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682)